E
Elena Nikiphorou
Researcher at King's College London
Publications - 263
Citations - 3444
Elena Nikiphorou is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 172 publications receiving 1849 citations. Previous affiliations of Elena Nikiphorou include Leiden University Medical Center & New Cross Hospital.
Papers
More filters
Journal ArticleDOI
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
Elena Nikiphorou,Helga Radner,Katerina Chatzidionysiou,Katerina Chatzidionysiou,Carole Desthieux,Codruta Zabalan,Yvonne van Eijk-Hustings,William G Dixon,Kimme L. Hyrich,Johan Askling,Johan Askling,Laure Gossec +11 more
TL;DR: Although PGA is associated with objective measures of disease activity, it is also associated with other aspects of health, such as psychological distress or comorbidities, which leads to situations of discordance between objective RA assessments and PGA.
Journal ArticleDOI
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts
Patrick A. Kiely,Amanda Busby,Elena Nikiphorou,Keith Sullivan,David A. Walsh,Paul Creamer,Josh Dixey,Adam Young +7 more
TL;DR: Exposure to methotrexate (MTX) treatment was not associated with an increased risk of rheumatoid arthritis interstitial lung disease (RA-ILD), and evidence suggested that MTX may delay the onset of ILD.
Journal ArticleDOI
A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome
TL;DR: Significant comorbidity was present at the outset of RA, increasing with follow-up, mainly in cardiovascular, non-cardiac vascular and respiratory systems, and needed earlier detection and management in order to reduce its impact on outcome.
Journal ArticleDOI
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A. Sparks,Zachary S. Wallace,Andrea M Seet,Milena A. Gianfrancesco,Zara Izadi,Kimme L. Hyrich,Anja Strangfeld,Laure Gossec,Loreto Carmona,Elsa F Mateus,Saskia Lawson-Tovey,Laura Trupin,Stephanie Rush,Patricia P. Katz,Gabriela Schmajuk,Lindsay Jacobsohn,Leanna Wise,Emily L Gilbert,Alí Duarte-García,Maria O Valenzuela-Almada,Guillermo J. Pons-Estel,Carolina A. Isnardi,Guillermo A. Berbotto,Tiffany Y.T. Hsu,Kristin M. D’Silva,Naomi J Patel,Lianne Kearsley-Fleet,Lianne Kearsley-Fleet,Martin Schäfer,Sandra Lúcia Euzébio Ribeiro,Samar Al Emadi,Liselotte Tidblad,Carlo Alberto Scirè,Bernd Raffeiner,Thierry Thomas,René Marc Flipo,Jérôme Avouac,Raphaèle Seror,Miguel Bernardes,Maria Margarida Cunha,Rebecca Hasseli,Hendrik Schulze-Koops,Ulf Müller-Ladner,Christof Specker,Viviane Angelina de Souza,Licia Maria Henrique da Mota,Ana Paula Monteiro Gomides,Philippe Dieudé,Elena Nikiphorou,Elena Nikiphorou,Vanessa L. Kronzer,Namrata Singh,Manuel F. Ugarte-Gil,Beth I Wallace,Akpabio Akpabio,Ranjeny Thomas,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Philip Robinson,Philip Robinson,Pedro Machado,Jinoos Yazdany +66 more
TL;DR: In this article, the authors investigated baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).
Journal ArticleDOI
EULAR definition of difficult-to-treat rheumatoid arthritis
György Nagy,Nadia M T Roodenrijs,Paco M J Welsing,Melinda Kedves,Attila Hamar,Marlies C van der Goes,Alison Kent,Margot Bakkers,Etienne Blaas,Ladislav Šenolt,Zoltán Szekanecz,Ernest Choy,Maxime Dougados,Johannes W G Jacobs,Rinie Geenen,Hans W J Bijlsma,Angela Zink,Daniel Aletaha,Leonard Schoneveld,Piet L. C. M. van Riel,Loriane Gutermann,Yeliz Prior,Elena Nikiphorou,Gianfranco Ferraccioli,Georg Schett,Kimme L. Hyrich,Ulf Mueller-Ladner,Maya H Buch,Iain B. McInnes,Désirée van der Heijde,Jacob M van Laar +30 more
TL;DR: The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.